Vaccitech


Vaccitech logo

Vaccitech is a spin-out company from the University of Oxford's Jenner institute, one of the oldest and most renowned vaccine research centres in the world.

The company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. Viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. The underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. The company's protected chimpanzee adenovirus technology is the best way to generate T-cell responses and thereby generate lasting cell-mediated immunity. The assets are already in the clinic with very promising initial results.

Contact Vaccitech via their website


News archive

29/10/2019   Vaccitech to present clinical development of Universal Influenza A Vaccine...more

27/08/2019   Vaccitech Appoints Bill Enright as New Chief Executive Officer...more

15/07/2019   Vaccitech appoints Mariem Charafeddine as Chief Medical Officer...more

05/06/2019   Vaccitech Universal flu vaccine passes Phase 2b milestones...more

15/05/2019   ProBioGen and Vaccitech Sign Technology Platform License Agreement...more

04/03/2019   Vaccitech Awarded BARDA contract for Phase II flu trial...more
28/02/2019   Vaccitech joins the BioPartner programme...more

The BioPartner Programme

BPP members enjoy our full range of discounts, enhanced promotion on BioPartner UK Delegations and first refusal on new international opportunities.

Not a member? Join the BioPartnership Programme

BioPartner UK is a member of

Sponsors Alliance

Prompt Payment Code